DexCom raises FY25 revenue guidance to $4.6B-$5.1B from $4B-$4.5B

Sees 2025 non-GAAP gross profit margin of 65%, consistent with prior guidance. Sees 2025 non-GAAP operating profit margin of 21%, previously 20%, and 2025 adjusted EBITDA margin of 31%, previously 30%. “Dexcom continues to execute on our vision to drive better health outcomes throughout the world through our innovative sensing technology,” said Kevin Sayer, Dexcom’s chairman, president and CEO. “Our growth opportunity is truly unique and we are pleased to be in a position to raise our 2025 financial targets as we grow our global customer base with an efficient and sustainable business model.”